Synergistic antimicrotubule therapy for prostate cancer

Biochemical Pharmacology

Volumn 81, Issue 4, 2011, Pages 478-487

  Pannu, Vaishali ^a   Karna, Prasanthi ^a   Sajja, Hari Krishna ^a   Shukla, Deep ^a   Aneja, Ritu ^a  

^a GEORGIA STATE UNIVERSITY   (United States)

Author keywords

Apoptosis; Docetaxel; Polyploidy; Synergy; Tubulin binding

Indexed keywords

ANTINEOPLASTIC AGENT; BROMONOSCAPINE; DOCETAXEL; EM 011; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW SUPPRESSION; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL CYCLE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DIOXOLES; HUMANS; ISOQUINOLINES; MALE; PROSTATIC NEOPLASMS; TAXOIDS; TUBULIN MODULATORS;

EID: 78751581881     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2010.11.006     Document Type: Article

References (46)

1. K. Lassi, and N.A. Dawson Update on castrate-resistant prostate cancer: 2010 Curr Opin Oncol 22 2010 263 267
2. R.D. Loberg, C.J. Logothetis, E.T. Keller, and K.J. Pienta Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype J Clin Oncol 23 2005 8232 8241
3. D.R. Berthold, C.N. Sternberg, and I.F. Tannock Management of advanced prostate cancer after first-line chemotherapy J Clin Oncol 23 2005 8247 8252
4. P.R. Carroll, P.W. Kantoff, S.P. Balk, M.A. Brown, A.V. D'Amico, and D.J. George Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer Urology 60 2002 1 6
5. D. Mazhar, and J. Waxman Early chemotherapy in prostate cancer Nat Clin Pract Urol 5 2008 486 493
6. S. Wilkinson, and G.W. Chodak Critical review of complementary therapies for prostate cancer J Clin Oncol 21 2003 2199 2210
7. T.M. Beer, W.C. Pierce, B.A. Lowe, and W.D. Henner Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer Ann Oncol 12 2001 1273 1279
8. D.P. Petrylak Chemotherapy for androgen-independent prostate cancer World J Urol 23 2005 10 13
9. R. Aneja, S. Asress, N. Dhiman, A. Awasthi, P.C.G. Rida, and S.K. Arora Non-toxic melanoma therapy by a novel tubulin-binding agent Int J Cancer 126 2010 256 265
10. A. Mancuso, S. Oudard, and C.N. Sternberg Effective chemotherapy for hormone-refractory prostate cancer (HRPC): present status and perspectives with taxane-based treatments Crit Rev Oncol Hematol 61 2007 176 185
11. C.N. Moore, and D.J. George Update in the management of patients with hormone-refractory prostate cancer Curr Opin Urol 15 2005 157 162
12. D.P. Petrylak Docetaxel for the treatment of hormone-refractory prostate cancer Rev Urol 5 2003 S14 21
13. S. Quasthoff, and H.P. Hartung Chemotherapy-induced peripheral neuropathy J Neurol 249 2002 9 17
14. E.K. Rowinsky The development and clinical utility of the taxane class of anti-microtubule chemotherapy agents Annu Rev Med 48 1997 353 374
15. M.A. Jordan, and L. Wilson Microtubules as a target for anticancer drugs Nat Rev Cancer 4 2004 253 265
16. E.A. Clark, P.M. Hills, B.S. Davidson, P.A. Wender, and S.L. Mooberry Laulimalide and synthetic laulimalide analogues are synergistic with paclitaxel and 2-methoxyestradiol Mol Pharm 3 2006 457 467
17. S. Honore, K. Kamath, D. Braguer, S.B. Horwitz, L. Wilson, and C. Briand Synergistic suppression of microtubule dynamics by discodermolide and paclitaxel in non-small cell lung carcinoma cells Cancer Res 64 2004 4957 4964
18. A. Wilmes, K. Bargh, C. Kelly, P.T. Northcote, J.H. Miller, and Peloruside A synergizes with other microtubule stabilizing agents in cultured cancer cell lines Mol Pharm 4 2007 269 280
19. K. Ye, Y. Ke, N. Keshava, J. Shanks, J.A. Kapp, and R.R. Tekmal Opium alkaloid noscapine is an antitumor agent that arrests metaphase and induces apoptosis in dividing cells Proc Natl Acad Sci U S A 95 1998 1601 1606
20. R. Aneja, M. Lopus, J. Zhou, S.N. Vangapandu, A. Ghaleb, and J. Yao Rational design of the microtubule-targeting anti-breast cancer drug EM015 Cancer Res 66 2006 3782 3791
21. R. Aneja, S.N. Vangapandu, M. Lopus, R. Chandra, D. Panda, and H.C. Joshi Development of a novel nitro-derivative of noscapine for the potential treatment of drug-resistant ovarian cancer and T-cell lymphoma Mol Pharmacol 69 2006 1801 1809
22. R. Aneja, S.N. Vangapandu, M. Lopus, V.G. Viswesarappa, N. Dhiman, and A. Verma Synthesis of microtubule-interfering halogenated noscapine analogs that perturb mitosis in cancer cells followed by cell death Biochem Pharmacol 72 2006 415 426
23. R. Aneja, J. Zhou, S.N. Vangapandu, B. Zhou, R. Chandra, and H.C. Joshi Drug-resistant T-lymphoid tumors undergo apoptosis selectively in response to an anti-microtubule agent, EM011 Blood 107 2006 2486 2492
24. R. Aneja, M. Liu, C. Yates, J. Gao, X. Dong, and B. Zhou Multidrug resistance-associated protein-overexpressing teniposide-resistant human lymphomas undergo apoptosis by a tubulin-binding agent Cancer Res 68 2008 1495 1503
25. R. Aneja, J. Zhou, B. Zhou, R. Chandra, and H.C. Joshi Treatment of hormone-refractory breast cancer: apoptosis and regression of human tumors implanted in mice Mol Cancer Ther 5 2006 2366 2377
26. T.C. Chou, and P. Talalay Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv Enzyme Regul 22 1984 27 55
27. R. Aneja, T. Miyagi, P. Karna, T. Ezell, D. Shukla, and M. Vij Gupta A novel microtubule-modulating agent induces mitochondrially driven caspase-dependent apoptosis via mitotic checkpoint activation in human prostate cancer cells Eur J Cancer 46 2010 194 204
28. P. Karna, S.M. Sharp, C. Yates, S. Prakash, and R. Aneja EM011 activates a survivin-dependent apoptotic program in human non-small cell lung cancer cells Mol Cancer 8 2009 93
29. M. Kavallaris Microtubules and resistance to tubulin-binding agents Nat Rev Cancer 10 2010 194 204
30. R.B. Ravelli, B. Gigant, P.A. Curmi, I. Jourdain, S. Lachkar, and A. Sobel Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain Nature 428 2004 198 202
31. S.L. Dixon, A.M. Smondyrev, E.H. Knoll, S.N. Rao, D.E. Shaw, and R.A. Friesner PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. methodology and preliminary results J Comput Aided Mol Des 20 2006 647 671
32. W.E. Dixon, and W. Malden Colchicine with special reference to its mode of action and effect on bone-marrow J Physiol 37 1908 50 76
33. E.C. Meng, E.F. Pettersen, G.S. Couch, C.C. Huang, and T.E. Ferrin Tools for integrated sequence-structure analysis with UCSF Chimera BMC Bioinformatics 7 2006 339
34. E.F. Pettersen, T.D. Goddard, C.C. Huang, G.S. Couch, D.M. Greenblatt, and E.C. Meng UCSF Chimera - a visualization system for exploratory research and analysis J Comput Chem 25 2004 1605 1612
35. J. Lowe, H. Li, K.H. Downing, and E. Nogales Refined structure of alpha beta-tubulin at 3.5 A resolution J Mol Biol 313 2001 1045 1057
36. R. Aneja, V. Kalia, R. Ahmed, and H.C. Joshi Nonimmunosuppressive chemotherapy: EM011-treated mice mount normal T-cell responses to an acute lymphocytic choriomeningitis virus infection Mol Cancer Ther 6 2007 2891 2899
37. Z.A. Stewart, and S.D. Leach Pietenpol JA. p21(Waf1/Cip1) inhibition of cyclin E/Cdk2 activity prevents endoreduplication after mitotic spindle disruption Mol Cell Biol 19 1999 205 215
38. Z.A. Stewart, D. Mays, and J.A. Pietenpol Defective G1-S cell cycle checkpoint function sensitizes cells to microtubule inhibitor-induced apoptosis Cancer Res 59 1999 3831 3837
39. C. Vaziri, S. Saxena, Y. Jeon, C. Lee, K. Murata, and Y. Machida A p53-dependent checkpoint pathway prevents rereplication Mol Cell 11 2003 997 1008
40. S.J. Rubin, D.E. Hallahan, C.R. Ashman, D.G. Brachman, M.A. Beckett, and S. Virudachalam Two prostate carcinoma cell lines demonstrate abnormalities in tumor suppressor genes J Surg Oncol 46 1991 31 36
41. J. Shi, J.D. Orth, and T. Mitchison Cell type variation in responses to antimitotic drugs that target microtubules and kinesin-5 Cancer Res 68 2008 3269 3276
42. H.C. Huang, J. Shi, J.D. Orth, and T.J. Mitchison Evidence that mitotic exit is a better cancer therapeutic target than spindle assembly Cancer Cell 16 2009 347 358
43. K.E. Gascoigne, and S.S. Taylor Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs Cancer Cell 14 2008 111 122
44. B.A. Weaver, and D.W. Cleveland Decoding the links between mitosis, cancer, and chemotherapy: the mitotic checkpoint, adaptation, and cell death Cancer Cell 8 2005 7 12
45. C.L. Hsieh, Z. Xie, Z.Y. Liu, J.E. Green, W.D. Martin, and M.W. Datta A luciferase transgenic mouse model: visualization of prostate development and its androgen responsiveness in live animals J Mol Endocrinol 35 2005 293 304
46. D.P. Petrylak The treatment of hormone-refractory prostate cancer: docetaxel and beyond Rev Urol 8 2006 S48 55